Last reviewed · How we verify
NCT04603209
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
trial testing Intraoperative Radiation Therapy (IORT) in Early-stage Breast Cancer in 1,000 participants. Currently enrolling.
3 October 2028
Quick facts
| Lead sponsor | Saint John's Cancer Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 3 October 2018 |
| Primary completion | 3 October 2028 |
| Estimated completion | 3 October 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Intraoperative Radiation Therapy (IORT)
Conditions studied
- Early-stage Breast Cancer — all drugs for Early-stage Breast Cancer →
- Breast Carcinoma in Situ — all drugs for Breast Carcinoma in Situ →
- Breast Neoplasms — all drugs for Breast Neoplasms →
Sponsor
Saint John's Cancer Institute
Who can join
18 and older, any sex, with Early-stage Breast Cancer or Breast Carcinoma in Situ. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, registry study that will enroll all women with early stage breast cancer who will be treated with intraoperative radiotherapy (IORT) during breast-conserving surgery. The purpose of this study is to further validate the long-term effectiveness and safety of this treatment method. We aim to assess short and long-term patient outcomes associated with IORT, including perioperative complications, local and distance disease recurrences, as well as disease-free survival and overall survival.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04603209
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Early-stage Breast Cancer
Currently open trials in the same condition.
- NCT06215469 — Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) · NA · recruiting
- NCT06144944 — Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer · Phase 3 · active not recruiting
- NCT06001762 — TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer · Phase 2 · active not recruiting
- NCT05957068 — Breast Cancer Exercise Intervention Study · NA · recruiting
- NCT06035016 — Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer · recruiting
Other Saint John's Cancer Institute trials
Trials by the same sponsor.
- NCT05289466 — Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With P · NA · terminated
- NCT03955042 — Pemetrexed for the Treatment of Chordoma · Phase 1 · completed
- NCT04082611 — The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition · NA · completed
- NCT03069287 — Integrating Family Caregiver Support Into Cancer Clinical Trials · NA · withdrawn
- NCT03371147 — CancerLife: Patient-Driven Solution in Cancer Care · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04603209 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Saint John's Cancer Institute
- Last refreshed: 16 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04603209.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing